Company Overview and News

 
14 years on, MBSB still unable to sell Melaka hotel

2018-10-02 theedgemarkets
IT has been 14 years since Malaysia Building Society Bhd (MBSB) placed the four-star Avillion Legacy Melaka Hotel — an asset it “inherited” as part of a loan settlement — up for sale, but it has yet to find a buyer.
1171

 
Melaka hotel still not sold, 14 years later

2018-09-24 theedgemarkets
THE four-star Avillion Legacy Melaka Hotel was put up for sale 14 years ago, by Malaysia Building Society (MBSB), but it has yet to find a buyer.
1171

 
Khazanah chief Shahril exits Media Prima, MBSB, MRCB

2018-08-21 theedgemarkets
KUALA LUMPUR: As he clocked in as Khazanah Nasional Bhd’s new managing director yesterday, Datuk Shahril Ridza Ridzuan resigned from the board of directors of three companies, namely Media Prima Bhd, Malaysia Building Society Bhd (MBSB) and Malaysian Resources Corp Bhd (MRCB) as their non-independent, non-executive director.
4502 MIAHF 1171 BSMAF 1818

 
Khazanah chief Shahril exits Media Prima, MBSB and MRCB

2018-08-20 theedgemarkets
KUALA LUMPUR (Aug 20): As he clocks in as Khazanah Nasional Bhd’s new managing director today, Datuk Shahril Ridza Ridzuan exits the board of directors of both Media Prima Bhd and Malaysia Building Society Bhd (MBSB) as their non-independent, non-executive director.
4502 MIAHF 1171 BSMAF 1818

 
Shahril resigns from Media Prima, MBSB and MRCB

2018-08-20 malaymail
KUALA LUMPUR, Aug 20 — Datuk Shahril Ridza Ridzuan has resigned as Non-Independent and Non-Executive Director of Media Prima Bhd, Malaysia Building Society Bhd (MBSB) and Malaysian Resources Corporation Bhd (MRCB), with immediate effect.
4502 MIAHF 1171 BSMAF 1818

 
Really, it’s the PM’s prerogative

2018-08-18 thestar.com.my
This puts to rest speculation as to whether the CEP, led by the 80-year Tun Daim Zainuddin would continue to chart the path of government linked companies (GLCs) and its parent companies, which are the government linked investment companies (GLICs).
1023 1171 CIMDF

 
Aabar offers to sell RHB shares at steep discount to entry cost

2018-08-15 theedgemarkets
KUALA LUMPUR: RHB Bank Bhd’s second largest shareholder Aabar Investments PJS is reducing its 17.75% equity stake in the banking group at a significant discount to its entry cost.
1023 1015 1171 AMMHF CIMDF

 
EPF's Shahril Ridza is Khazanah's new MD, confirms The Edge Financial Daily report

2018-08-03 theedgemarkets
KUALA LUMPUR (Aug 3): Khazanah Nasional Bhd has appointed Datuk Shahril Ridza Ridzuan, currently the chief executive officer (CEO) of the Employees Provident Fund (EPF), as managing director (MD) of the sovereign wealth fund effective Aug 20.
4502 MIAHF 1171

 
MBSB 3Q, 4Q results seen to reflect loan loss provisions

2018-08-01 theedgemarkets
Malaysia Building Society Bhd (July 31, RM1.12) Maintain hold with a lower fair value (FV) of RM1.27: Malaysia Building Society Bhd’s (MBSB) net profit for the second quarter of financial year 2018 (2QFY18) fell 71.8% quarter-on-quarter (q-o-q) due to a charge in impairment allowances for loans of RM124 milliion compared to a net write-back in provisions of RM154 million in 1QFY18, and higher operating expenses (Opex) from integration cost and amortisation of information technology (IT) investments.
1171

 
MBSB 2Q net profit down 6% on lower gross loans and financing

2018-07-31 theedgemarkets
KUALA LUMPUR: Malaysia Building Society Bhd (MBSB) saw its net profit fall 5.9% to RM85.69 million in the second quarter ended June 30, 2018 (2QFY18) from RM91.08 million a year ago, on lower gross loans and financing for 2QFY18.
1171 BSMAF 1818

 
MBSB down after group said 2Q net profit fell on year

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): Malaysia Building Society Bhd (MBSB) shares fell as much as four sen or 3% so far today after the financial services provider said yesterday second quarter net profit dropped to RM85.69 million from RM91.08 million a year earlier.
1171 BSMAF 1818

 
KLCI seen opening lower, tracking global markets, support at 1,750

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): The FBM KLCI is seen opening lower today, tracking the overnight losses at most global markets.
6084 7251 7060 7113 TPGVF 1171 0173 7253 4022 TGLVY 5216 4723 BSMAF 1818

 
MBSB second quarter net profit slips to RM85.7mil

2018-07-30 thestar.com.my
KUALA LUMPUR: Malaysia Building Society Bhd 's (MBSB) net profit for the second quarter ended June 30, 2018, slid to RM85.68mil from RM91.08mil recorded in the same period last year.
1171 BSMAF 1818

 
Top Glove, JAKS, Star Media, MBSB, Barakah Offshore, Handal Resources, Fima Corp, Datasonic, New Hoong Fatt, Rev Asia and Tadmax

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): Based on corporate announcements and news flow today, companies in focus on Tuesday (July 31) may include: Top Glove Corp Bhd, JAKS Resources Bhd, Star Media Group Bhd, Malaysia Building Society Bhd, Barakah Offshore Petroleum Bhd, Handal Resources Bhd, Fima Corp Bhd, Datasonic Group Bhd, New Hoong Fatt Holdings Bhd, Rev Asia Bhd and Tadmax Resources Bhd
6084 7251 7060 7113 TPGVF 1171 0173 7253 4022 TGLVY 5216 4723 WWDH

 
MBSB 2Q net profit down 6% on lower gross loans and financing

2018-07-30 theedgemarkets
KUALA LUMPUR (July 30): Malaysia Building Society Bhd (MBSB) saw its net profit fall 5.9% to RM85.69 million in the second quarter ended June 30, 2018 (2QFY18) from RM91.08 million a year ago, on lower gross loans and financing for 2QFY18.
1171 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...